News
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced first quarter 2025 financial results and provided a business update. "Our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback